ALLに対する化学療法無しの治療法の支持を強化する第III相データ

|December 17, 2025

Abstract:

In the phase III GIMEMA ALL2820 trial, treatment with ponatinib and blinatumomab led to significantly better response rates and overall survival than a chemotherapy-imatinib regimen for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. The findings could change the standard of care for the disease.

キーワード:

ポナチニブブリンツモマブフィラデルフィア染色体陽性ALL 第III相試験急性リンパ芽球性白血病分子標的治療化学療法無しの治療法

さらに関連する動画

06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K

08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.5K

関連する概念動画

02:56

Treatment Resistant Cancers

3.7K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

3.7K